FY2025 · ended Dec 31, 2025 · Revenue $75.13M, +160.6% YoY · Filed Feb 24, 2026
AbCellera Biologics Inc. (ABCL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $75.1 million and a net loss of $146.4 million. Free cash flow was -$174.1 million. As of Jun 30, 2026 it held $540.1 million in cash and investments and $135.6 million in total debt.
Revenue (TTM)
$66.17M
+101.3% vs year-ago TTM
Net income (TTM)
$-164.66M
+0.6% vs year-ago TTM
Operating cash flow (TTM)
$-94.94M
-17.4% vs year-ago TTM
Free cash flow (TTM)
$-119.67M
+13.9% vs year-ago TTM
EPS (TTM)
$-0.55
+2.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
303.16M
+1.7% vs prior year
Net cash
$404.49M
as of Jun 30, 2026
Operating margin
-340.3%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABCL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1703057
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M |
| Operating income | -$217.1M | -$314.8M | -$237.2M | $216.5M | $204.4M |
| Net income | -$146.4M | -$162.9M | -$146.4M | $158.5M | $153.5M |
| Diluted EPS | -$0.49 | -$0.55 | -$0.51 | $0.50 | $0.48 |
| Operating cash flow | -$131.3M | -$108.6M | -$43.9M | $277.4M | $244.6M |
| Free cash flow | -$174.1M | -$187.0M | -$120.8M | $206.7M | $186.1M |
| Total assets | $1.4B | $1.4B | $1.5B | $1.5B | $1.3B |
| Total liabilities | $390.0M | $304.5M | $335.8M | $307.6M | $292.8M |
| Stockholders' equity | $966.9M | $1.1B | $1.2B | $1.2B | $1.0B |
| Cash and investments | $533.8M | $625.6M | $760.6M | $886.5M | $723.0M |
| Total debt | $143.2M | $65.4M | $77.4M | $82.3M | $40.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
Aug 13, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Aug 7, 2026 | Aug 7, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Other events
|
Jul 29, 2026 | Jul 29, 2026 |
All 322 AbCellera Biologics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.